Effect of mutation on diagnosis, risk stratification, and treatment decisions in Philadelphia-negative myeloproliferative neoplasms.

Abstract excerpt

Since the discovery of the activating mutation of JAK2, known as JAK2V617F, our understanding of mutation profiles, and the biological significance of this mutation in Philadelphia-negative (Ph-) MPNs has drastically changed over the last decade. Mutations of the thrombopoietin receptor MPL and chaperone protein calreticulin gene also induce aberrant activation of JAK and downstream molecules, including STAT...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to JAK2 gene
• Share to MPL gene
• Share to Mutation